Company Overview and News
UEM Sunrise Bhd has proposed the disposal of 28.995 acres of freehold agricultural lands in Iskandar Puteri, Johor Baru, to Kimlun Corp Bhd for a total consideration of RM82.1mil.
MarketWatch: Wall Street pulled back from record-high territory on Monday, weighed down by a drop in Merck shares and a report that US lawmakers are discussing a gradual phase-in of much-anticipated corporate tax cuts. The DJIA fell 85.45 points, or 0.36%, to 23,348.74, the S&P 500 lost 8.24 points, or 0.32%, to 2,572.83 and the Nasdaq dropped 2.30 points, or 0.03%, to 6,698.96. - Reuters
KUALA LUMPUR (Jan 19): The FBM KLCI is expected to extend its gains today, riding on its current momentum but any advance may be capped by caution ahead of the inauguration of Donald Trump on Friday.
KUALA LUMPUR (Jan 18): Based on corporate announcements and news flow today, companies that may be in focus on Thursday (Jan 19) include Silk Holdings, Gadang Holdings, Genting, Mesiniaga, WCT Holdings, Axiata, Uzma, Guocoland, Spring Gallery, Country View, FSBM Holdings, Tex Cycle, Green Packet and Yen Global.
KUALA LUMPUR (July 27): The FBM KLCI is expected to remain cautious today in line with the overnight mixed closed at global markets.
KUALA LUMPUR (July 26): Based on corporate announcements and news flow today, companies that may be in focus tomorrow (July 27) could include the following: BAT, Country View, Globetronics, Puncak Niaga, Melati Ehsan, IGB REIT and Yinson.
2018-05-25 - Asif
Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...
2018-05-25 - Asif
Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...